Your browser doesn't support javascript.
loading
Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort.
Idahl, Annika; Le Cornet, Charlotte; González Maldonado, Sandra; Waterboer, Tim; Bender, Noemi; Tjønneland, Anne; Hansen, Louise; Boutron-Ruault, Marie-Christine; Fournier, Agnès; Kvaskoff, Marina; Boeing, Heiner; Trichopoulou, Antonia; Valanou, Elisavet; Peppa, Eleni; Palli, Domenico; Agnoli, Claudia; Mattiello, Amalia; Tumino, Rosario; Sacerdote, Carlotta; Onland-Moret, N Charlotte; Gram, Inger T; Weiderpass, Elisabete; Quirós, Jose R; Duell, Eric J; Sánchez, Maria-Jose; Chirlaque, Maria-Dolores; Barricarte, Aurelio; Gil, Leire; Brändstedt, Jenny; Riesbeck, Kristian; Lundin, Eva; Khaw, Kay-Tee; Perez-Cornago, Aurora; Gunter, Marc J; Dossus, Laure; Kaaks, Rudolf; Fortner, Renée T.
Affiliation
  • Idahl A; Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.
  • Le Cornet C; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • González Maldonado S; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Waterboer T; Infections and Cancer Epidemiology, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Bender N; Infections and Cancer Epidemiology, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Tjønneland A; Danish Cancer Society Research Center, Diet, Genes and Environment (DGE), Copenhagen, Germany.
  • Hansen L; Danish Cancer Society Research Center, Diet, Genes and Environment (DGE), Copenhagen, Germany.
  • Boutron-Ruault MC; CESP, Faculté de Médecine, Université Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
  • Fournier A; Gustave Roussy, Villejuif, France.
  • Kvaskoff M; CESP, Faculté de Médecine, Université Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
  • Boeing H; Gustave Roussy, Villejuif, France.
  • Trichopoulou A; CESP, Faculté de Médecine, Université Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
  • Valanou E; Gustave Roussy, Villejuif, France.
  • Peppa E; Department of Epidemiology, German Institute of Human Nutrition (DIfE) Potsdam-Rehbrücke, Nuthetal, Germany.
  • Palli D; Hellenic Health Foundation, Athens, Greece.
  • Agnoli C; Hellenic Health Foundation, Athens, Greece.
  • Mattiello A; Hellenic Health Foundation, Athens, Greece.
  • Tumino R; Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Cancer Risk Factors and Life-Style Epidemiology Unit, Florence, Italy.
  • Sacerdote C; Istituto Nazionale dei Tumori di Milano Via Venezian, Epidemiology and Prevention Unit Fondazione IRCCS, Milan, Italy.
  • Onland-Moret NC; Dipartimento di Medicina Clinica e Chirurgia, Federico II university, Naples, Italy.
  • Gram IT; Cancer Registry and Histopathology Department, "Civic - M.P. Arezzo" Hospital, ASP, Ragusa, Italy.
  • Weiderpass E; Unit of Cancer Epidemiology, Città Della Salute e Della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy.
  • Quirós JR; Julius Center for Health Sciences and Primary Care, UMC Utrecht, YOUth onderzoek - Universiteit Utrecht, Utrecht, The Netherlands.
  • Duell EJ; Faculty of Health Sciences, Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
  • Sánchez MJ; International Agency for Research on Cancer, Lyon, France.
  • Chirlaque MD; J.S. Información Sanitaria, Dirección General de Salud Pública, Consejería de Sanidad, Oviedo, Spain.
  • Barricarte A; Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.
  • Gil L; Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain.
  • Brändstedt J; CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Riesbeck K; CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Lundin E; Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia, Spain.
  • Khaw KT; Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain.
  • Perez-Cornago A; CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Gunter MJ; Navarra Public Health Institute, Pamplona, Spain.
  • Dossus L; Navarra Institute for Health Research (IdiSNA) Pamplona, Spain.
  • Kaaks R; Public Health Division of Gipuzkoa, Research institute of BioDonostia, San Sebastian, Spain.
  • Fortner RT; Department of Clinical Sciences, Lund University, Division of Surgery, Skåne University Hospital, Lund, Sweden.
Int J Cancer ; 147(8): 2042-2052, 2020 10 15.
Article in En | MEDLINE | ID: mdl-32243586
ABSTRACT
A substantial proportion of epithelial ovarian cancer (EOC) arises in the fallopian tube and other epithelia of the upper genital tract; these epithelia may incur damage and neoplastic transformation after sexually transmitted infections (STI) and pelvic inflammatory disease. We investigated the hypothesis that past STI infection, particularly Chlamydia trachomatis, is associated with higher EOC risk in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort including 791 cases and 1669 matched controls. Serum antibodies against C. trachomatis, Mycoplasma genitalium, herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV) 16, 18 and 45 were assessed using multiplex fluorescent bead-based serology. Conditional logistic regression was used to estimate relative risks (RR) and 95% confidence intervals (CI) comparing women with positive vs. negative serology. A total of 40% of the study population was seropositive to at least one STI. Positive serology to C. trachomatis Pgp3 antibodies was not associated with EOC risk overall, but with higher risk of the mucinous histotype (RR = 2.30 [95% CI = 1.22-4.32]). Positive serology for chlamydia heat shock protein 60 (cHSP60-1) was associated with higher risk of EOC overall (1.36 [1.13-1.64]) and with the serous subtype (1.44 [1.12-1.85]). None of the other evaluated STIs were associated with EOC risk overall; however, HSV-2 was associated with higher risk of endometrioid EOC (2.35 [1.24-4.43]). The findings of our study suggest a potential role of C. trachomatis in the carcinogenesis of serous and mucinous EOC, while HSV-2 might promote the development of endometrioid disease.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Chlamydia Infections / Sexually Transmitted Diseases / Chlamydia trachomatis Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Int J Cancer Year: 2020 Document type: Article Affiliation country: Suecia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Chlamydia Infections / Sexually Transmitted Diseases / Chlamydia trachomatis Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Int J Cancer Year: 2020 Document type: Article Affiliation country: Suecia